{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:15:25Z","timestamp":1792181725554,"version":"4.4.0"},"reference-count":184,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.coviro.2020.09.003","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T07:37:03Z","timestamp":1604043423000},"page":"169-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Rhabdoviruses as vectors for vaccines and therapeutics"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7571-4791","authenticated-orcid":false,"given":"Gabrielle","family":"Scher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias J","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2020.09.003_bib0005","series-title":"Virology","first-page":"1137","article-title":"Rhabdoviruses","author":"Dietzschold","year":"1996"},{"key":"10.1016\/j.coviro.2020.09.003_bib0010","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(13)62707-5","article-title":"Current status of rabies and prospects for elimination","volume":"384","author":"Fooks","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.coviro.2020.09.003_bib0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/13550280290100725","article-title":"Rabies pathogenesis","volume":"8","author":"Jackson","year":"2002","journal-title":"J Neurovirol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0020","series-title":"WHO Expert Consultation on Rabies, Second Report","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.coviro.2020.09.003_bib0025","series-title":"Istorical Perspective of Rabies in Europe and the Mediterranean Basin","first-page":"1","article-title":"Rabies in the ancient world","author":"Neville","year":"2004"},{"key":"10.1016\/j.coviro.2020.09.003_bib0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1128\/br.16.3.179-204.1952","article-title":"The natural history of vesicular stomatitis","volume":"16","author":"Hanson","year":"1952","journal-title":"Bacteriol Rev"},{"key":"10.1016\/j.coviro.2020.09.003_bib0035","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1128\/jvi.64.4.1716-1725.1990","article-title":"Role of matrix protein in cytopathogenesis of vesicular stomatitis virus","volume":"64","author":"Blondel","year":"1990","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/13550280701460565","article-title":"Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection","volume":"13","author":"Trottier","year":"2007","journal-title":"J Neurovirol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0045","doi-asserted-by":"crossref","first-page":"12554","DOI":"10.1128\/JVI.79.19.12554-12565.2005","article-title":"Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system","volume":"79","author":"Wang","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0050","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1002\/j.1460-2075.1994.tb06739.x","article-title":"Infectious rabies viruses from cloned cDNA","volume":"13","author":"Schnell","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.coviro.2020.09.003_bib0055","first-page":"513","article-title":"Vaccinia virus-free recovery of vesicular stomatitis virus","volume":"3","author":"Harty","year":"2001","journal-title":"J Mol Microbiol Biotechnol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0060","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1128\/JVI.75.23.11496-11502.2001","article-title":"Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein","volume":"75","author":"Mebatsion","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0065","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.1073\/pnas.93.14.7310","article-title":"Highly stable expression of a foreign gene from rabies virus vectors","volume":"93","author":"Mebatsion","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0070","doi-asserted-by":"crossref","first-page":"11359","DOI":"10.1073\/pnas.93.21.11359","article-title":"Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles","volume":"93","author":"Schnell","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2020.09.003_bib0075","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0092-8674(00)80349-9","article-title":"A CXCR4\/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells","volume":"90","author":"Mebatsion","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2020.09.003_bib0080","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.micinf.2016.12.004","article-title":"A recombinant vesicular stomatitis virus encoding CCR5-tropic HIV-1 receptors targets HIV-1-infected cells and controls HIV-1 infection","volume":"19","author":"Okuma","year":"2017","journal-title":"Microbes Infect"},{"key":"10.1016\/j.coviro.2020.09.003_bib0085","series-title":"First FDA-Approved Vaccine for the Prevention of Ebola Virus Disease, Marking a Critical Milestone in Public Health Preparedness and Response","year":"2019"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0090","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa\u2013Rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Abreu-Mota","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2020.09.003_bib0095","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1586\/14760584.2016.1140040","article-title":"Current status and development of vaccines and other biologics for human rabies prevention","volume":"15","author":"Rupprecht","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2020.09.003_bib0100","series-title":"The Private Science of Louis Pasteur","author":"Geison","year":"2014"},{"key":"10.1016\/j.coviro.2020.09.003_bib0105","series-title":"WHO Prequalified Vaccines","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.coviro.2020.09.003_bib0110","first-page":"142","article-title":"Purified chick embryo cell (PCEC) rabies vaccine for human use. Laboratory data","volume":"76","author":"Barth","year":"1984","journal-title":"Behring Inst Mitt"},{"key":"10.1016\/j.coviro.2020.09.003_bib0115","series-title":"Improvements in Rabies Post-Exposure Treatment","first-page":"115","article-title":"A new vaccine produced from rabies virus cultivated on vero cells","author":"Fournier","year":"1985"},{"key":"10.1016\/j.coviro.2020.09.003_bib0120","series-title":"Adaptation of Pitman Moore Strain of Rabies Virus To Primary Chick Embryo Fibroblast Cell Cultures","author":"Patel","year":"2010"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0125","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/14760584.2017.1294068","article-title":"Development of a new purified vero cell rabies vaccine (Rabivax-S) at the serum institute of India Pvt Ltd","volume":"16","author":"Kulkarni","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2020.09.003_bib0130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.tmaid.2007.07.004","article-title":"Preventing rabies with the Verorab\u00ae vaccine: 1985\u20132005","volume":"5","author":"Toovey","year":"2007","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0135","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1016\/j.vaccine.2016.08.005","article-title":"A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes","volume":"34","author":"Bose","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0140","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4161\/hv.26456","article-title":"Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman-Moore strain) manufactured in India","volume":"10","author":"Ashwath Narayana","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.coviro.2020.09.003_bib0145","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/14760584.2015.1011134","article-title":"30 years of rabies vaccination with Rabipur: a summary of clinical data and global experience","volume":"14","author":"Giesen","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0150","article-title":"Rabies","volume":"3","author":"Fooks","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.coviro.2020.09.003_bib0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.vaccine.2015.11.036","article-title":"Worldwide rabies deaths prevention\u2014a focus on the current inadequacies in postexposure prophylaxis of animal bite victims","volume":"34","author":"Wilde","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0160","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0165","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.antiviral.2013.04.004","article-title":"Control and prevention of canine rabies: the need for building laboratory-based surveillance capacity","volume":"98","author":"Banyard","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0170","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.vaccine.2017.02.014","article-title":"Rationale and support for a One Health program for canine vaccination as the most cost-effective means of controlling zoonotic rabies in endemic settings","volume":"35","author":"Lavan","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0264-410X(95)00197-9","article-title":"Immunization coverage required to prevent outbreaks of dog rabies","volume":"14","author":"Coleman","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0180","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1371\/journal.pbio.1000053","article-title":"Transmission dynamics and prospects for the elimination of canine rabies","volume":"7","author":"Hampson","year":"2009","journal-title":"PLoS Biol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0185","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2017.00052","article-title":"Rabies vaccination targets for stray dog populations","volume":"4","author":"Leung","year":"2017","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.coviro.2020.09.003_bib0190","series-title":"Oral Vaccination of Dogs Against Rabies. Guidance for Research on Oral Rabies Vaccines and Field Application of Oral Vaccination of Dogs Against Rabies","author":"World Health Organization","year":"2007"},{"key":"10.1016\/j.coviro.2020.09.003_bib0195","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1126\/science.1256306","article-title":"Implementing Pasteur\u2019s vision for rabies elimination","volume":"345","author":"Lankester","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0200","doi-asserted-by":"crossref","first-page":"421","DOI":"10.20506\/rst.37.2.2812","article-title":"Rabies control in North America \u2013 past, present and future","volume":"37","author":"Fehlner-Gardiner","year":"2018","journal-title":"Rev Sci Tech l\u2019OIE"},{"key":"10.1016\/j.coviro.2020.09.003_bib0205","series-title":"Report of the Scientific Committee on Animal Health and Animal Welfare","article-title":"The oral vaccination of foxes against rabies","author":"Commission E","year":"2002"},{"key":"10.1016\/j.coviro.2020.09.003_bib0210","series-title":"European Pharmacopoeia","first-page":"736","article-title":"Rabies vaccines (live, oral) for foxes","year":"2008"},{"key":"10.1016\/j.coviro.2020.09.003_bib0215","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1016\/j.vaccine.2006.12.054","article-title":"The safety and efficacy of the oral rabies vaccine SAG2 in Indian stray dogs","volume":"25","author":"Cliquet","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001535","article-title":"Eliminating rabies in Estonia","volume":"6","author":"Cliquet","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0225","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1128\/JVI.77.1.237-244.2003","article-title":"Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 Gag have greatly reduced pathogenicity but are highly immunogenic","volume":"77","author":"McGettigan","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0230","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1086\/605949","article-title":"Replication\u2010deficient rabies virus\u2013based vaccines are safe and immunogenic in mice and nonhuman primates","volume":"200","author":"Cenna","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0235","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/tropicalmed2030037","article-title":"Pathogenicity and immunogenicity of recombinant rabies viruses expressing the Lagos bat virus matrix and glycoprotein: perspectives for a pan-lyssavirus vaccine","volume":"2","author":"Kgaladi","year":"2017","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006398","article-title":"Replication-incompetent rabies virus vector harboring glycoprotein gene of lymphocytic choriomeningitis virus (LCMV) protects mice from LCMV challenge","volume":"12","author":"Takayama-Ito","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0245","doi-asserted-by":"crossref","first-page":"10605","DOI":"10.1128\/JVI.00558-11","article-title":"Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses","volume":"85","author":"Blaney","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0250","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/v11100919","article-title":"Genetically modified rabies virus vector-based rift valley fever virus vaccine is safe and induces efficacious immune responses in mice","volume":"11","author":"Zhang","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2020.09.003_bib0255","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.virol.2006.05.010","article-title":"Rabies virus glycoprotein as a carrier for anthrax protective antigen","volume":"353","author":"Smith","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0260","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-00248-6","article-title":"Rabies virus-based COVID-19 vaccine CORAVAX\u2122 induces high levels of neutralizing antibodies against SARS-CoV-2","volume":"5","author":"Kurup","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.coviro.2020.09.003_bib0265","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1016\/j.vaccine.2010.03.039","article-title":"The immune response to rabies virus infection and vaccination","volume":"28","author":"Johnson","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0270","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","article-title":"Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines","volume":"169","author":"Whitt","year":"2010","journal-title":"J Virol Methods"},{"key":"10.1016\/j.coviro.2020.09.003_bib0275","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.vaccine.2015.12.006","article-title":"Efficient generation of vesicular stomatitis virus (VSV)-pseudotypes bearing morbilliviral glycoproteins and their use in quantifying virus neutralising antibodies","volume":"34","author":"Logan","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0280","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00705-016-2803-1","article-title":"Analysis of the entry mechanism of Crimean-Congo hemorrhagic fever virus, using a vesicular stomatitis virus pseudotyping system","volume":"161","author":"Suda","year":"2016","journal-title":"Arch Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0285","doi-asserted-by":"crossref","first-page":"11607","DOI":"10.1038\/s41598-017-10865-2","article-title":"Analysis of VSV pseudotype virus infection mediated by rubella virus envelope proteins","volume":"7","author":"Sakata","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2020.09.003_bib0290","doi-asserted-by":"crossref","first-page":"10321","DOI":"10.1128\/JVI.01714-16","article-title":"Characterization of vesicular stomatitis virus pseudotypes bearing essential entry glycoproteins gB, gD, gH, and gL of herpes simplex virus 1","volume":"90","author":"Rogalin","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0295","first-page":"259","article-title":"Study of receptors for vesicular stomatitis virus in vertebrate and invertebrate cells","volume":"9","author":"Seganti","year":"1986","journal-title":"Microbiologica"},{"key":"10.1016\/j.coviro.2020.09.003_bib0300","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.virusres.2013.06.003","article-title":"Understanding and altering cell tropism of vesicular stomatitis virus","volume":"176","author":"Hastie","year":"2013","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2020.09.003_bib0305","doi-asserted-by":"crossref","first-page":"10057","DOI":"10.1073\/pnas.93.19.10057","article-title":"Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system","volume":"93","author":"Chen","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2020.09.003_bib0310","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.coph.2015.08.003","article-title":"Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells","volume":"24","author":"L\u00e9vy","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0315","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1016\/S0021-9258(17)41741-8","article-title":"Fusogenic virosomes prepared by partitioning of vesicular stomatitis virus G protein into preformed vesicles","volume":"269","author":"Hug","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2020.09.003_bib0320","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/mt.2011.138","article-title":"Protein transfer into human cells by VSV-G-induced nanovesicles","volume":"19","author":"Mangeot","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0325","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41467-018-07845-z","article-title":"Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins","volume":"10","author":"Mangeot","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0330","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.omtm.2018.10.006","article-title":"Surface-engineered lentiviral vectors for selective gene transfer into subtypes of lymphocytes","volume":"12","author":"Frank","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0335","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s12010-016-2246-x","article-title":"Incorporation of viral glycoprotein VSV-G improves the delivery of DNA by erythrocyte ghost into cells refractory to conventional transfection","volume":"181","author":"Liu","year":"2017","journal-title":"Appl Biochem Biotechnol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0340","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/mt.2008.59","article-title":"Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus\u2013vectored tuberculosis vaccine","volume":"16","author":"Roediger","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2020.09.003_bib0345","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0092-8674(01)00482-2","article-title":"An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants","volume":"106","author":"Rose","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2020.09.003_bib0350","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus\u2013based vaccines against Ebola and Marburg virus infections","volume":"204","author":"Geisbert","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0355","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","article-title":"Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses","volume":"78","author":"Garbutt","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0360","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2020.09.003_bib0365","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses","volume":"26","author":"Geisbert","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005547","article-title":"Mucosal immunization of cynomolgus macaques with the VSVDeltaG\/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses","volume":"4","author":"Qiu","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2020.09.003_bib0375","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2020.09.003_bib0380","doi-asserted-by":"crossref","first-page":"S1066","DOI":"10.1093\/infdis\/jir348","article-title":"Vesicular stomatitis virus\u2013based Ebola vaccines with improved cross-protective efficacy","volume":"204","author":"Marzi","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0385","doi-asserted-by":"crossref","first-page":"S1082","DOI":"10.1093\/infdis\/jir350","article-title":"Single immunization with a monovalent vesicular stomatitis virus\u2013based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus","volume":"204","author":"Falzarano","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002600","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus","volume":"7","author":"Mire","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0395","doi-asserted-by":"crossref","first-page":"E819","DOI":"10.1503\/cmaj.170074","article-title":"Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial","volume":"189","author":"ElSherif","year":"2017","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.coviro.2020.09.003_bib0400","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2020.09.003_bib0405","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/nm.4201","article-title":"Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies","volume":"22","author":"Khurana","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2020.09.003_bib0410","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2020.09.003_bib0415","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0420","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/infdis\/jix189","article-title":"Six-month safety data of recombinant vesicular stomatitis virus\u2013Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults","volume":"215","author":"Halperin","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0425","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0430","article-title":"A single dose of recombinant VSV-\u0394G-spike vaccine provides protection against SARS-CoV-2 challenge","author":"Yahalom-Ronen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.coviro.2020.09.003_bib0435","first-page":"1492","article-title":"Fusogenic Membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth","volume":"60","author":"Bateman","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.coviro.2020.09.003_bib0440","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/77558","article-title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","volume":"6","author":"Stojdl","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0445","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/v10020090","article-title":"Oncotargeting by vesicular stomatitis virus (VSV): advances in cancer therapy","volume":"10","author":"Bishnoi","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2020.09.003_bib0450","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ijc.22680","article-title":"Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2\/neu","volume":"121","author":"Bergman","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0455","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00705-020-04585-8","article-title":"Construction of a replication-competent retroviral vector for expression of the VSV-G envelope glycoprotein for cancer gene therapy","volume":"165","author":"Jin","year":"2020","journal-title":"Arch Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0460","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/JVI.02308-14","article-title":"Rhabdovirus-based vaccine platforms against henipaviruses","volume":"89","author":"Kurup","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0465","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1128\/JVI.72.6.4704-4711.1998","article-title":"Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge","volume":"72","author":"Roberts","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0470","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01865-18","article-title":"A recombinant rabies virus expressing the Marburg virus glycoprotein is dependent upon antibody-mediated cellular cytotoxicity for protection against Marburg virus disease in a murine model","volume":"93","author":"Keshwara","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0475","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41541-019-0109-5","article-title":"Rabies-based vaccine induces potent immune responses against Nipah virus","volume":"4","author":"Keshwara","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0480","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02040-16","article-title":"One-health: a safe, efficient, dual-use vaccine for humans and animals against Middle East Respiratory Syndrome Coronavirus and rabies virus","volume":"91","author":"Wirblich","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0485","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02077-16","article-title":"Inactivated recombinant rabies viruses displaying canine distemper virus glycoproteins induce protective immunity against both pathogens","volume":"91","author":"da Fontoura Budaszewski","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0490","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1016\/j.vaccine.2016.07.020","article-title":"Two potential recombinant rabies vaccines expressing canine parvovirus virion protein 2 induce immunogenicity to canine parvovirus and rabies virus","volume":"34","author":"Luo","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0495","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.vetmic.2014.10.023","article-title":"Recombinant rabies virus expressing the H protein of canine distemper virus protects dogs from the lethal distemper challenge","volume":"174","author":"Wang","year":"2014","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0500","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1016\/j.vaccine.2011.04.045","article-title":"Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge","volume":"29","author":"Mustafa","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0505","doi-asserted-by":"crossref","first-page":"14046","DOI":"10.1038\/mtm.2014.46","article-title":"Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo","volume":"1","author":"Hudacek","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.coviro.2020.09.003_bib0510","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.virol.2012.07.020","article-title":"A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence","volume":"434","author":"Papaneri","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2020.09.003_bib0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003389","article-title":"Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine","volume":"9","author":"Blaney","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2020.09.003_bib0520","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.1093\/infdis\/jiv251","article-title":"Preclinical development of inactivated rabies virus\u2013based polyvalent vaccine against rabies and filoviruses","volume":"212","author":"Willet","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0525","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1093\/infdis\/jiw231","article-title":"An inactivated rabies virus-based Ebola vaccine, FILORAB1, adjuvanted with glucopyranosyl lipid A in stable emulsion confers complete protection in nonhuman primate challenge models","volume":"214","author":"Johnson","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0530","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1016\/j.vaccine.2009.09.025","article-title":"Development of combined vaccines for rabies and immunocontraception","volume":"27","author":"Wu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0535","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1099\/vir.0.80844-0","article-title":"A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies","volume":"86","author":"Faber","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0540","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/aid.2014.0319","article-title":"A bivalent, chimeric rabies virus expressing simian immunodeficiency virus envelope induces multifunctional antibody responses","volume":"31","author":"Dunkel","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.coviro.2020.09.003_bib0545","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.vaccine.2009.10.051","article-title":"Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIVmac251 challenge","volume":"28","author":"Faul","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0550","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1086\/512243","article-title":"Highly attenuated rabies virus\u2013based vaccine vectors expressing simian\u2010human immunodeficiency virus 89.6P Env and simian immunodeficiency virus mac239 Gag are safe in rhesus macaques and protect from an AIDS\u2010like disease","volume":"195","author":"McKenna","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0555","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.virol.2004.10.018","article-title":"Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime\u2013boost approach","volume":"331","author":"Tan","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2020.09.003_bib0560","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.virol.2005.09.004","article-title":"Enhanced humoral HIV-1-specifc immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2","volume":"344","author":"McGettigan","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2020.09.003_bib0565","doi-asserted-by":"crossref","first-page":"12782","DOI":"10.1128\/JVI.77.23.12782-12794.2003","article-title":"Covalently linked human immunodeficiency virus type 1 gp120\/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes","volume":"77","author":"McKenna","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0570","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1128\/JVI.77.20.10889-10899.2003","article-title":"Functional human immunodeficiency virus type 1 (HIV-1) Gag-pol or HIV-1 Gag-pol and Env expressed from a single rhabdovirus-based vaccine vector genome","volume":"77","author":"McGettigan","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0575","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/viro.2001.1212","article-title":"Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines","volume":"292","author":"Siler","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2020.09.003_bib0580","doi-asserted-by":"crossref","first-page":"8724","DOI":"10.1128\/JVI.75.18.8724-8732.2001","article-title":"Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector","volume":"75","author":"McGettigan","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0585","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1128\/JVI.75.9.4430-4434.2001","article-title":"Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates","volume":"75","author":"McGettigan","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0590","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067123","article-title":"Comparison of heterologous prime-boost strategies against human immunodeficiency virus type 1 Gag using negative stranded RNA viruses","volume":"8","author":"Lawrence","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2020.09.003_bib0595","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/JVI.73.1.225-233.1999","article-title":"Chimeric lyssavirus glycoproteins with increased immunological potential","volume":"73","author":"Jallet","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0600","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1128\/jvi.69.3.1444-1451.1995","article-title":"Mokola virus glycoprotein and chimeric proteins can replace rabies virus glycoprotein in the rescue of infectious defective rabies virus particles","volume":"69","author":"Mebatsion","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0605","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/v11070645","article-title":"Vesicular stomatitis virus-based vaccines provide cross-protection against Andes and Sin Nombre viruses","volume":"11","author":"Warner","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0610","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-44210-6","article-title":"Vesicular stomatitis virus-based vaccine protects mice against Crimean-Congo hemorrhagic fever","volume":"9","author":"Rodriguez","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0615","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.virol.2019.05.009","article-title":"Recombinant vesicular stomatitis virus expressing the spike protein of genotype 2b porcine epidemic diarrhea virus: a platform for vaccine development against emerging epidemic isolates","volume":"533","author":"Ke","year":"2019","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0620","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29401-x","article-title":"A VSV-based Zika virus vaccine protects mice from lethal challenge","volume":"8","author":"Emanuel","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0625","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1016\/j.vaccine.2018.05.095","article-title":"A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections","volume":"36","author":"Chattopadhyay","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0630","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12250-019-00083-7","article-title":"A vesicular stomatitis virus-based vaccine carrying zika virus capsid protein protects mice from viral infection","volume":"34","author":"Shi","year":"2019","journal-title":"Virol Sin"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0635","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.antiviral.2017.12.007","article-title":"A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization","volume":"150","author":"Liu","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0640","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00479-17","article-title":"Vesicular stomatitis virus Pseudotyped with Ebola virus glycoprotein serves as a protective, noninfectious vaccine against Ebola virus challenge in mice","volume":"91","author":"Lennemann","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0645","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01729-16","article-title":"Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single-dose protection against lethal alphavirus challenge","volume":"91","author":"Nasar","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0650","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.4049\/jimmunol.1602180","article-title":"Cutting edge: innate immune augmenting vesicular stomatitis virus expressing Zika virus proteins confers protective immunity","volume":"198","author":"Betancourt","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0655","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1016\/j.vaccine.2016.06.058","article-title":"Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges","volume":"34","author":"Yan","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0660","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1080\/21645515.2016.1183857","article-title":"Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection","volume":"12","author":"Lauretti","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.coviro.2020.09.003_bib0665","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13567-016-0318-0","article-title":"Virus replicon particles expressing porcine reproductive and respiratory syndrome virus proteins elicit immune priming but do not confer protection from viremia in pigs","volume":"47","author":"Eck","year":"2016","journal-title":"Vet Res"},{"key":"10.1016\/j.coviro.2020.09.003_bib0670","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003736","article-title":"A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses","volume":"9","author":"Safronetz","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004011","article-title":"Use of recombinant virus replicon particles for vaccination against Mycobacterium ulcerans disease","volume":"9","author":"Bolz","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0680","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1016\/j.vaccine.2015.03.089","article-title":"Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease","volume":"33","author":"Prescott","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0685","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1297-9716-45-64","article-title":"Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection","volume":"45","author":"Kochinger","year":"2014","journal-title":"Vet Res"},{"key":"10.1016\/j.coviro.2020.09.003_bib0690","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1016\/j.vaccine.2014.05.052","article-title":"A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis","volume":"32","author":"Wu","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0695","doi-asserted-by":"crossref","first-page":"12781","DOI":"10.1128\/JVI.00794-11","article-title":"Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus","volume":"85","author":"Brown","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0700","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1128\/JVI.02523-10","article-title":"Vesicular stomatitis virus-simian retrovirus type 2 vaccine protects macaques from detectable infection and B-cell destruction","volume":"85","author":"Gautam","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0705","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1128\/JVI.02332-10","article-title":"Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus","volume":"85","author":"Ma","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0710","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1128\/JVI.00019-14","article-title":"Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector","volume":"88","author":"Ma","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0715","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1128\/JVI.00200-10","article-title":"A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose","volume":"84","author":"Cobleigh","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0720","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1128\/JVI.02111-12","article-title":"A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice","volume":"87","author":"Cobleigh","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0725","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1128\/JVI.01572-09","article-title":"Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens","volume":"84","author":"Braxton","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0730","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1099\/vir.0.009019-0","article-title":"Expression and processing of human immunodeficiency virus type 1 gp160 using the vesicular stomatitis virus New Jersey serotype vector system","volume":"90","author":"Wu","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0735","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1128\/CVI.00451-08","article-title":"Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces CD8 T-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus","volume":"16","author":"Barefoot","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0740","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1128\/JVI.03246-14","article-title":"A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine","volume":"89","author":"Ryder","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0745","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.vaccine.2008.12.019","article-title":"A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1)","volume":"27","author":"Kalhoro","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0750","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066059","article-title":"Vaccination with recombinant RNA replicon particles protects chickens from H5N1 highly pathogenic avian influenza virus","volume":"8","author":"Halbherr","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2020.09.003_bib0755","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.vaccine.2008.11.087","article-title":"Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01","volume":"27","author":"Iyer","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0760","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2008.03.002","article-title":"SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector","volume":"376","author":"Kapadia","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2020.09.003_bib0765","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1128\/JVI.00456-08","article-title":"Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates","volume":"82","author":"Geisbert","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0770","first-page":"129","article-title":"Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity","volume":"58","author":"Wilson","year":"2008","journal-title":"Comp Med"},{"key":"10.1016\/j.coviro.2020.09.003_bib0775","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1128\/CVI.00343-07","article-title":"Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein","volume":"15","author":"Liao","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0780","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/JVI.01515-07","article-title":"Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and G gene truncation reduces neurovirulence and enhances immunogenicity in mice","volume":"82","author":"Cooper","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0785","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv082","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 Gag vaccine (HVTN 090)","volume":"2","author":"Fuchs","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.coviro.2020.09.003_bib0790","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1128\/JVI.02835-06","article-title":"Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus","volume":"81","author":"Brandsma","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0795","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.vaccine.2006.08.012","article-title":"Therapeutic efficacy of vesicular stomatitis virus-based E6 vaccination in rabbits","volume":"25","author":"Brandsma","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0800","doi-asserted-by":"crossref","first-page":"8345","DOI":"10.1016\/j.vaccine.2009.04.082","article-title":"Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and\/or vesicular stomatitis virus vectors","volume":"28","author":"Brandsma","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0805","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.vaccine.2006.08.010","article-title":"An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge","volume":"25","author":"Palin","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0810","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1016\/j.vaccine.2008.09.031","article-title":"Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection","volume":"26","author":"Chattopadhyay","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0815","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.bbrc.2005.11.067","article-title":"Elicitation of neutralizing antibodies by intranasal administration of recombinant vesicular stomatitis virus expressing human immunodeficiency virus type 1 gp120","volume":"339","author":"Jiang","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.coviro.2020.09.003_bib0820","doi-asserted-by":"crossref","first-page":"13231","DOI":"10.1128\/JVI.79.21.13231-13238.2005","article-title":"A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector","volume":"79","author":"Publicover","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0825","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1128\/JVI.00959-06","article-title":"Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine","volume":"80","author":"Daddario-DiCaprio","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0830","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.virol.2005.06.016","article-title":"Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine","volume":"340","author":"Kapadia","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2020.09.003_bib0835","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.vaccine.2005.08.006","article-title":"Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment","volume":"24","author":"Luo","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0840","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/JVI.78.8.3930-3940.2004","article-title":"Highly effective control of an aids virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol","volume":"78","author":"Ramsburg","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0845","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.vaccine.2009.11.061","article-title":"Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV","volume":"28","author":"Van Rompay","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.09.003_bib0850","doi-asserted-by":"crossref","first-page":"8900","DOI":"10.1128\/JVI.76.17.8900-8909.2002","article-title":"Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease","volume":"76","author":"Reuter","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0855","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1128\/JVI.78.6.3196-3199.2004","article-title":"Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein","volume":"78","author":"Roberts","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0860","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1128\/JVI.76.14.6865-6872.2002","article-title":"Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins","volume":"76","author":"Buonocore","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0865","doi-asserted-by":"crossref","first-page":"11079","DOI":"10.1128\/JVI.75.22.11079-11087.2001","article-title":"Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge","volume":"75","author":"Kahn","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0870","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.imlet.2012.12.005","article-title":"Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice","volume":"150","author":"Johnson","year":"2013","journal-title":"Immunol Lett"},{"key":"10.1016\/j.coviro.2020.09.003_bib0875","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0168-1702(00)00164-7","article-title":"Presence of bovine viral diarrhea virus (BVDV) E2 glycoprotein in VSV recombinant particles and induction of neutralizing BVDV antibodies in mice","volume":"69","author":"Grigera","year":"2000","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2020.09.003_bib0880","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/JVI.74.10.4652-4657.2000","article-title":"Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies","volume":"74","author":"Schlereth","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0885","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1099\/vir.0.19050-0","article-title":"Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose","volume":"84","author":"Schlereth","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0890","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1006\/viro.1999.0120","article-title":"Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope","volume":"268","author":"Haglund","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2020.09.003_bib0895","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1128\/JVI.76.6.2730-2738.2002","article-title":"High-level primary CD8+ T-cell response to human immunodeficiency virus type 1 Gag and Env generated by vaccination with recombinant vesicular stomatitis viruses","volume":"76","author":"Haglund","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0900","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.virol.2007.04.021","article-title":"Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection","volume":"366","author":"Schwartz","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2020.09.003_sbref0905","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41541-019-0155-z","article-title":"A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades","volume":"5","author":"Furuyama","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.coviro.2020.09.003_bib0910","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1128\/jvi.71.7.5060-5068.1997","article-title":"Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins","volume":"71","author":"Johnson","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0915","doi-asserted-by":"crossref","first-page":"10903","DOI":"10.1128\/JVI.74.23.10903-10910.2000","article-title":"Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1","volume":"74","author":"Rose","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.09.003_bib0920","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-virology-100114-055157","article-title":"Everything you always wanted to know about rabies virus (but were afraid to ask)","volume":"2","author":"Davis","year":"2015","journal-title":"Annu Rev Virol"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625720300936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625720300936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:04:39Z","timestamp":1761818679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625720300936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":184,"alternative-id":["S1879625720300936"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2020.09.003","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rhabdoviruses as vectors for vaccines and therapeutics","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2020.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}